spacer
spacer

PDBsum entry 3bjc

Go to PDB code: 
protein ligands metals links
Hydrolase PDB id
3bjc

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
311 a.a. *
Ligands
WAN
Metals
_ZN
_MG
Waters ×116
* Residue conservation analysis
PDB id:
3bjc
Name: Hydrolase
Title: Crystal structure of the pde5a catalytic domain in complex with a novel inhibitor
Structure: Cgmp-specific 3',5'-cyclic phosphodiesterase. Chain: a. Synonym: cgb-pde, cgmp-binding cgmp-specific phosphodiesterase. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: pde5a, pde5. Expressed in: escherichia coli bl21. Expression_system_taxid: 511693.
Resolution:
2.00Å     R-factor:   0.197     R-free:   0.221
Authors: G.Chen,H.Wang,R.Howard,J.Cai,Y.Wan,H.Ke
Key ref: G.Chen et al. (2008). An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies. Biochem Pharmacol, 75, 1717-1728. PubMed id: 18346713
Date:
03-Dec-07     Release date:   29-Apr-08    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
O76074  (PDE5A_HUMAN) -  cGMP-specific 3',5'-cyclic phosphodiesterase from Homo sapiens
Seq:
Struc:
 
Seq:
Struc:
875 a.a.
311 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: E.C.3.1.4.35  - 3',5'-cyclic-GMP phosphodiesterase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: 3',5'-cyclic GMP + H2O = GMP + H+
3',5'-cyclic GMP
+ H2O
= GMP
+ H(+)
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    Added reference    
 
 
Biochem Pharmacol 75:1717-1728 (2008)
PubMed id: 18346713  
 
 
An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.
G.Chen, H.Wang, H.Robinson, J.Cai, Y.Wan, H.Ke.
 
  ABSTRACT  
 
Selective inhibitors of cyclic nucleotide phosphodiesterase-5 (PDE5) have been used as drugs for treatment of male erectile dysfunction and pulmonary hypertension. An insight into the pharmacophores of PDE5 inhibitors is essential for development of second generation of PDE5 inhibitors, but has not been completely illustrated. Here we report the synthesis of a new class of the sildenafil derivatives and a crystal structure of the PDE5 catalytic domain in complex with 5-(2-ethoxy-5-(sulfamoyl)-3-thienyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (12). Inhibitor 12 induces conformational change of the H-loop (residues 660-683), which is different from any of the known PDE5 structures. The pyrazolopyrimidinone groups of 12 and sildenafil are well superimposed, but their sulfonamide groups show a positional difference of as much as 1.5A. The structure-activity analysis suggests that a small hydrophobic pocket and the H-loop of PDE5 are important for the inhibitor affinity, in addition to two common elements for binding of almost all the PDE inhibitors: the stack against the phenylalanine and the hydrogen bond with the invariant glutamine. However, the PDE5-12 structure does not provide a full explanation to affinity changes of the inhibitors. Thus alternatives such as conformational change of the M-loop are open and further structural study is required.
 

Literature references that cite this PDB file's key reference

  PubMed id Reference
19936959 A.L.Williams, S.R.Dandepally, and S.V.Kotturi (2010).
A p-methoxybenzyl (PMB) protection/deprotection approach toward the synthesis of 5-phenoxy-4-chloro-N-(aryl/alkyl) thiophene-2-sulfonamides.
  Mol Divers, 14, 697-707.  
20818684 C.Roegler, and J.Lehmann (2010).
[Medicinal chemistry of nitrates and PDE5 inhibitors].
  Pharm Unserer Zeit, 39, 351-358.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.

 

spacer

spacer